Originele taal-2 | English |
---|---|
Pagina's (van-tot) | 191-194 |
Aantal pagina's | 4 |
Tijdschrift | Allergy |
Volume | 75 |
Nummer van het tijdschrift | 1 |
Vroegere onlinedatum | 22-jun.-2019 |
DOI's | |
Status | Published - 1-jan.-2020 |
Toegang tot document
- Nasal gene expression changes with inhaled corticosteroid treatment in asthmaFinal author's version, 295 KBLicentie: Unspecified
Handle.net
Nasal gene expression changes with inhaled corticosteroid treatment in asthma
Final publisher's version, 648 KB
Document onder embargo
Citeer dit
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Nasal gene expression changes with inhaled corticosteroid treatment in asthma. / Boudewijn, Ilse M; Lan, Andy; Faiz, Alen et al.
In: Allergy, Vol. 75, Nr. 1, 01.01.2020, blz. 191-194.Onderzoeksoutput › Academic › peer review
TY - JOUR
T1 - Nasal gene expression changes with inhaled corticosteroid treatment in asthma
AU - Boudewijn, Ilse M
AU - Lan, Andy
AU - Faiz, Alen
AU - Cox, Claire A
AU - Brouwer, Sharon
AU - Schokker, Siebrig
AU - Vroegop, Sebastiaan J
AU - Nawijn, Martijn C
AU - Woodruff, Prescott G
AU - Christenson, Stephanie A
AU - Hagedoorn, Paul
AU - Frijlink, Henderik W
AU - Choy, David F
AU - Brouwer, Uilke
AU - Wisman, Marissa
AU - Postma, Dirkje S
AU - Fingleton, James
AU - Beasley, Richard
AU - van den Berge, Maarten
AU - Guryev, Victor
N1 - Funding Information: The OLiVIA study was funded by TEVA pharmaceutical Industries Ltd. The NZRHS study was funded by the Health Research Council of New Zealand (grant no 10/174), Astra Zeneca Ltd and Genentech. MvdB reports grants paid to the University from Astra Zeneca, TEVA, GSK, and Chiesi. IMB reports consultancy fees paid to the University from GSK. MCN reports grants paid to the University from GSK. PGW reports a grant from Medimmune and consultancy fees from Astra Zeneca, Regeneron, Sanofi, Genentech, Novartis, and Glemmark. SAC reports a grant from Medimmune, fees from Astra Zeneca and nonfinancial support from Genentech. PH is involved in development and design of the Twincer high-dose dry powder inhaler, and his employer receives royalties from the sales of the Novolizer and Genuair. HWF has a patent WO2003/000325 with royalties paid to Astra-Zeneca and his employer receives royalties from the sales of Genuair products. DFC is an employee of Genentech and has submitted patents for methods for the diagnosis and treatment of respiratory disease patients. DSP reports grants paid to the University from Astra Zeneca, Chiesi, Genentech, GSK, and Roche and reports consultancy fees paid to the University by Astra Zeneca, Chiesi, and GSK. JF reports grants from Health Research Council of New Zealand, AstraZeneca, GSK, Fisher & Paykel, and Genentech; fees from AstraZeneca and Boehringer-Ingelheim and nonfinancial support from Novartis and Boehringer-Ingelheim. RB reports grants from Health Research Council of New Zealand, Astra Zeneca, GSK, and Genentech and fees from Astra Zeneca. AL, AF, CAC, SB, SS, SJV, UB, MW, and VG have nothing to disclose.
PY - 2020/1/1
Y1 - 2020/1/1
U2 - 10.1111/all.13952
DO - 10.1111/all.13952
M3 - Letter
C2 - 31230369
VL - 75
SP - 191
EP - 194
JO - Allergy
JF - Allergy
SN - 0105-4538
IS - 1
ER -